|
[1] WHO. Global hepatitis report,2017[EB/OL].[2019-11-06]. https://www. who. int/hepatitis/publications/globalhepatitis-report2017/en/．
|
|
[2] CUI F,SHEN L,LI L,et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy,China[J].Emerg Infect Dis,2017,23(5):765-772.
|
|
[3] LIU J,LIANG W,JING W,et al. Countdown to 2030:Eliminating hepatitis B disease,China[J]. Bull World Health Organ,2019,97(3):230-238.
|
|
[4] XU Y,LIU H,WANG Y,et al. The next step in controlling HBV in China[J/OL]. BMJ,2013,347:f4503.
|
|
[5] LU Y,ZHU FC,LIU JX,et al. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources:A large prospective cohort study in China[J]. Vaccine,2017,35(48 Pt B):6627-6633.
|
|
[6] TERRAULT NA,LOK ASF,MCMAHON BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology,2018,67(4):1560-1599.
|
|
[7] SCHILLIE S,VELLOZZIC,REINGOLD A,et al. Prevention of hepatitis B virus infection in the United States:Recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Recomm Rep,2018,67(1):1-31.
|
|
[8] WHO. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[M]. Geneva:World Health organization,2015.
|
|
[9] National Health and Family Planning Commission,National Development and Reform Commission,Ministry of Education,et al. Action plan for the prevention and treatment of viral hepatitis in China(2017—2020)[J]. Chin J Viral Dis,2018,8(1):1-5.(in Chinese)国家卫生计生委，国家发展改革委，教育部，等．中国病毒性肝炎防治规划(2017-2020年)[J]．中国病毒病杂志，2018,8(1):1-5.
|
|
[10] World Health Organization. Hepatitis B vaccines:WHO position paper,July 2017-Recommendations[J]. Vaccine,2019,37(2):223-225.
|
|
[11] BRUCE MG,BRUDEN D,HURLBURT D,et al. Antibody levels and protection after hepatitis B vaccine:Results of a 30-year follow-up study and response to a booster dose[J]. J Infect Dis,2016,214(1):16-22.
|
|
[12] LEVY M,KOREN G. Hepatitis B vaccine in pregnancy:Maternal and fetal safety[J]. Am J Perinatol,1991,8(3):227-232.
|
|
[13] MORO PL,ZHETEYEVA Y,BARASH F,et al. Assessing the safety of hepatitis B vaccination during pregnancy in the Vaccine Adverse Event Reporting System(VAERS),1990-2016[J]. Vaccine,2018,36(1):50-54.
|
|
[14] SHEFFIELD JS,HICKMAN A,TANG J,et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy[J]. Obstet Gynecol,2011,117(5):1130-1135.
|
|
[15] YAN H,ZHONG G,XU G,et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J/OL]. Elife,2012,1:e00049.
|
|
[16] GIERSCH K,ALLWEISS L,VOLZ T,et al. Serum HBV pgRNA as a clinical marker for cccDNA activity[J]. J Hepatol,2017,66(2):460-462.
|
|
[17] LU FM,WANG J,ZHUANG H. Potential clinical significance of serum HBV RNA virus-like particles[J]. Chin J Hepatol,2016,24(9):641-642.(in Chinese)鲁凤民，王杰，庄辉．HBV RNA病毒样颗粒的潜在临床意义[J]．中华肝脏病杂志，2016,24(9):641-642.
|
|
[18] LU FM,DOU XG,ZHANG WH,et al. Clinical significance of serum HBV RNA measurement in chronic hepatitis B patients[J]. J Clin Hepatol,2018,34(5):934-938.(in Chinese)鲁凤民，窦晓光，张文宏，等．慢性乙型肝炎患者血清HBV RNA检测的临床意义[J]．临床肝胆病杂志，2018,34(5):934-938.
|
|
[19] MCNAUGHTON AL,D’ARIENZO V,ANSARI MA,et al. Insights from deep sequencing of the HBV genome-unique,tiny,and misunderstood[J]. Gastroenterology,2019,156(2):384-399.
|
|
[20] LIN CL,KAO JH. The clinical implications of hepatitis B virus genotype:Recent advances[J]. J Gastroenterol Hepatol,2011,26(Suppl 1):123-130.
|
|
[21] LIVINGSTON SE,SIMONETTI JP,BULKOW LR,et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A,B,C,D,and F[J]. Gastroenterology,2007,133(5):1452-1457.
|
|
[22] YU MW,YEH SH,CHEN PJ,et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma:A prospective study in men[J]. J Natl Cancer Inst,2005,97(4):265-272.
|
|
[23] TANG LSY,COVERT E,WILSON E,et al. Chronic hepatitis B infection:A review[J]. JAMA,2018,319(17):1802-1813.
|
|
[24] INDOLFI G,EASTERBROOK P,DUSHEIKO G,et al. Hepatitis B virus infection in children and adolescents[J]. Lancet Gastroenterol Hepatol,2019,4(6):466-476.
|
|
[25] NAYAGAM S,THURSZ M,SICURI E,et al. Requirements for global elimination of hepatitis B:A modelling study[J]. Lancet Infect Dis,2016,16(12):1399-1408.
|
|
[26] LIU JF,YAO NJ,CHEN TY,et al. Prevalence of mother-tochild transmission of hepatitis B virus:A systematic review and meta-analysis[J]. J Hepatol,2019,70(Suppl 1):e123-e124.
|
|
[27] Chinese Society of Infectious Diseases,Chinese Medical Association; Chinese GRADE Center. Guidelines for the prevention and treatment of mother-to-child transmission of hepatitis B virus in China(version 2019)[J]. Chin J Infect Dis,2019,37(7):388-396.(in Chinese)中华医学会感染病学分会，GRADE中国中心．中国乙型肝炎病毒母婴传播防治指南(2019年版)[J]．中华传染病杂志，2019,37(7):388-396.
|
|
[28] LIAW YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J]. Liver Int,2009,29(Suppl 1):100-107.
|
|
[29] FANNING GC,ZOULIM F,HOU J,et al. Therapeutic strategies for hepatitis B virus infection:Towards a cure[J]. Nat Rev Drug Discov,2019,18(11):827-844.
|
|
[30] HUI CK,LEUNG N,YUEN ST,et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology,2007,46(2):395-401.
|
|
[31] LIAW YF. Hepatitis flares and hepatitis B e antigen seroconversion:Implication in anti-hepatitis B virus therapy[J]. J Gastroenterol Hepatol,2003,18(3):246-252.
|
|
[32] CHU CM,HUNG SJ,LIN J,et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J]. Am J Med,2004,116(12):829-834.
|
|
[33] CHU CM,LIAW YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers[J]. Clin Infect Dis,2012,54(1):88-90.
|
|
[34] CHU CM,LIAW YF. Hepatitis B surface antigen seroclearance during chronic HBV infection[J]. Antivir Ther,2010,15(2):133-143.
|
|
[35] FATTOVICH G,BORTOLOTTI F,DONATO F. Natural history of chronic hepatitis B:Special emphasis on disease progression and prognostic factors[J]. J Hepatol,2008,48(2):335-352.
|
|
[36] CHEN YC,CHU CM,LIAW YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J]. Hepatology,2010,51(2):435-444.
|
|
[37] PARK BK,PARK YN,AHN SH,et al. Long-term outcome of chronic hepatitis B based on histological grade and stage[J]. J Gastroenterol Hepatol,2007,22(3):383-388.
|
|
[38] LIN SM,YU ML,LEE CM,et al. Interferon therapy in HBe Ag positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma[J]. J Hepatol,2007,46(1):45-52.
|
|
[39] CHU CM,LIAW YF. Hepatitis B virus-related cirrhosis:Natural history and treatment[J]. Semin Liver Dis,2006,26(2):142-152.
|
|
[40] CHEN YC,CHU CM,YEH CT,et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B:A long-term follow-up study[J]. Hepatol Int,2007,1(1):267-273.
|
|
[41] HSU YS,CHIEN RN,YEH CT,et al. Long-term outcome after spontaneous HBe Ag seroconversion in patients with chronic hepatitis B[J]. Hepatology,2002,35(6):1522-1527.
|
|
[42] McMAHON BJ,HOLCK P,BULKOW L,et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus[J]. Ann Intern Med,2001,135(9):759-768.
|
|
[43] FATTOVICH G,GIUSTINA G,SCHALM SW,et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP study group on hepatitis B virus and cirrhosis[J]. Hepatology,1995,21(1):77-82.
|
|
[44] FATTOVICH G. Natural history and prognosis of hepatitis B[J]. Semin Liver Dis,2003,23(1):47-58.
|
|
[45] TSENG TC,LIU CJ,YANG HC,et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads[J]. Hepatology,2013,57(2):441-450.
|
|
[46] TSENG TC,LIU CJ,YANG HC,et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load[J]. Gastroenterology,2012,142(5):1140-1149,e3.
|
|
[47] ZHANG Z,ZHANG JY,WANG LF,et al. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection[J]. J Gastroenterol Hepatol,2012,27(2):223-230.
|
|
[48] DANDRI M,LOCARNINI S. New insight in the pathobiology of hepatitis B virus infection[J]. Gut,2012,61(Suppl 1):i6-i17.
|
|
[49] ISOGAWA M,TANAKA Y. Immunobiology of hepatitis B virus infection[J]. Hepatol Res,2015,45(2):179-189.
|
|
[50] GUIDOTTI LG,CHISARI FV. Noncytolytic control of viral infections by the innate and adaptive immune response[J]. Annu Rev Immunol,2001,19:65-91.
|
|
[51] BERTOLETTI A,FERRARI C. Innate and adaptive immune responses in chronic hepatitis B virus infections:Towards restoration of immune control of viral infection[J]. Gut,2012,61(12):1754-1764.
|
|
[52] CORNBERG M,WONG VW,LOCARNINI S,et al. The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol,2017,66(2):398-411.
|
|
[53] HOU JL,ZHAO W,LEE C,et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol,2019.[Epub ahead of print]
|
|
[54] KIM JH,SINN DH,KANG W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology,2017,66(2):335-343.
|
|
[55] WIEGAND J,HASENCLEVER D,TILLMANN HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence[J]. Antivir Ther,2008,13(2):211-220.
|
|
[56] NI YH,CHANG MH,WANG KJ,et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma[J]. Gastroenterology,2004,127(6):1733-1738.
|
|
[57] CHU CJ,HUSSAIN M,LOK AS. Hepatitis B virus genotype B is associated with earlier HBe Ag seroconversion compared with hepatitis B virus genotype C[J]. Gastroenterology,2002,122(7):1756-1762.
|
|
[58] WATANABE K,TAKAHASHI T,TAKAHASHI S,et al. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations[J]. J Gastroenterol Hepatol,2005,20(3):441-449.
|
|
[59] RAJORIYA N,COMBET C,ZOULIM F,et al. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?[J]. J Hepatol,2017,67(6):1281-1297.
|
|
[60] JIA W,SONG LW,FANG YQ,et al. Antibody to hepatitis B core antigen levels in the natural history of chronic hepatitis B:A prospective observational study[J]. Medicine(Baltimore),2014,93(29):e322.
|
|
[61] SONG LW,LIU PG,LIU CJ,et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection[J]. Clin Microbiol Infect,2015,21(2):197-203.
|
|
[62] FAN R,SUN J,YUAN Q,et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut,2016,65(2):313-320.
|
|
[63] HOU FQ,SONG LW,YUAN Q,et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBe Ag-positive chronic hepatitis B patients receiving peginterferon[J]. Theranostics,2015,5(3):218-226.
|
|
[64] ZHOU J,SONG L,ZHAO H,et al. Serum hepatitis B core antibody as a biomarker of hepatic inflammation in chronic hepatitis B patients with normal alanine aminotransferase[J]. Sci Rep,2017,7(1):2747.
|
|
[65] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.
|
|
[66] FAN R,ZHOU B,XU M,et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy[J]. Clin Gastroenterol Hepatol,2019.[Epub ahead of print]
|
|
[67] WONG DK,SETO WK,CHEUNG KS,et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA[J]. Liver Int,2017,37(7):995-1001.
|
|
[68] MARTINOT-PEIGNOUX M,LAPALUS M,MAYLIN S,et al.Baseline HBs Ag and HBcrAg titres allow peginterferon-based‘precision medicine’in HBe Ag-negative chronic hepatitis B patients[J]. J Viral Hepat,2016,23(11):905-911.
|
|
[69] HONDA M,SHIRASAKI T,TERASHIMA T,et al. Hepatitis B virus(HBV)core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma[J]. J Infect Dis,2016,213(7):1096-1106.
|
|
[70] CHUAYPEN N,POSUWAN N,PAYUNGPORN S,et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBe Ag-positive chronic hepatitis B[J]. Liver Int,2016,36(6):827-836.
|
|
[71] KWO PY,COHEN SM,LIM JK. ACG clinical guideline:Evaluation of abnormal liver chemistries[J]. Am J Gastroenterol,2017,112(1):18-35.
|
|
[72] WANG K,LIN W,KUANG Z,et al. Longitudinal change of body mass index is associated with alanine aminotransferase elevation after complete viral suppression in chronic hepatitis B patients[J]. J Infect Dis,2019,220(9):1469-1476.
|
|
[73] AMADDEO G,CAO Q,LADEIRO Y,et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas[J]. Gut,2015,64(5):820-829.
|
|
[74] SEO SI,KIM HS,KIM WJ,et al. Diagnostic value of PIVKAII and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma[J]. World J Gastroenterol,2015,21(13):3928-3935.
|
|
[75] WAI CT,CHENG CL,WEE A,et al. Non-invasive models for predicting histology in patients with chronic hepatitis B[J].Liver Int,2006,26(6):666-672.
|
|
[76] KIM WR,BERG T,ASSELAH T,et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol,2016,64(4):773-780.
|
|
[77] DONG XQ,WU Z,ZHAO H,et al. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients[J]. J Viral Hepat,2019,26(2):297-307.
|
|
[78] SONNEVELD MJ,BROUWER WP,CHAN HL,et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B:Results from the SONIC-B study[J]. Lancet Gastroenterol Hepatol,2019,4(7):538-544.
|
|
[79] LEMOINE M,SHIMAKAWA Y,NAYAGAM S,et al. The gamma-glutamyl transpeptidase to platelet ratio(GPR)predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa[J]. Gut,2016,65(8):1369-1376.
|
|
[80] CHEN YP,HU XM,LIANG XE,et al. Stepwise application of fibrosis index based on four factors,red cell distribution width-platelet ratio,and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection[J]. J Gastroenterol Hepatol,2018,33(1):256-263.
|
|
[81] YAO M,WANG L,YOU H,et al. Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B[J]. Clin Chim Acta,2019,493:92-97.
|
|
[82] WANG L,LIU T,ZHOU J,et al. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy[J]. Hepatol Res,2018,48(3):e283-e290.
|
|
[83] YAN L,DENG Y,ZHOU J,et al. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT[J]. Infection,2018,46(3):385-393.
|
|
[84] European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol,2015,63(1):237-264.
|
|
[85] Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Disease,Chinese Medical Association; Chinese Society of Hepatology,Chinese Medical Association,et al. Consensus on clinical application of transient elastography detecting liver fibrosis:A 2018 update[J]. Chin J Hepatol,2019,27(3):182-191.(in Chinese)中国肝炎防治基金会，中华医学会感染病学分会，中华医学会肝病学分会，等．瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]．中华肝脏病杂志，2019,27(3):182-191.
|
|
[86] CHEN YP,LIANG XE,DAI L,et al. Improving transient elastography performance for detecting hepatitis B cirrhosis[J].Dig Liver Dis,2012,44(1):61-66.
|
|
[87] CHEN YP,LIANG XE,ZHANG Q,et al. Larger biopsies evaluation of transient elastography for detecting advanced fibrosis in patients with compensated chronic hepatitis B[J]. J Gas troenterol Hepatol,2012,27(7):1219-1226.
|
|
[88] CHAN HL,WONG GL,CHOI PC,et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography(Fibroscan)for liver fibrosis in chronic hepatitis B[J]. J Viral Hepat,2009,16(1):36-44.
|
|
[89] LIANG XE,ZHONG C,HUANG L,et al. Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers[J]. J Gastroenterol Hepatol,2017,32(2):459-465.
|
|
[90] SCOTT DR,LEVY MT. Liver transient elastography(Fibroscan):A place in the management algorithms of chronic viral hepatitis[J]. Antivir Ther,2010,15(1):1-11.
|
|
[91] WU Z,DONG X,WANG G,et al. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal[J]. J Viral Hepat,2019,26(2):287-296.
|
|
[92] JIA J,HOU J,DING H,et al. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B[J]. J Gastroenterol Hepatol,2015,30(4):756-762.
|
|
[93] FETZER DT,RODGERS SK,SEOW JH,et al. Ultrasound evaluation in patients at risk for hepatocellular carcinoma[J]. Radiol Clin North Am,2019,57(3):563-583.
|
|
[94] ELSAYES KM,KIELAR AZ,CHERNYAK V,et al. LI-RADS:A conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance[J]. J Hepatocell Carcinoma,2019,6:49-69.
|
|
[95] KNODELL RG,ISHAK KG,BLACK WC,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology,1981,1(5):431-435.
|
DownLoad: